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In eukaryotic flap endonuclease 1, the C terminus is essential for
substrate binding
Abstract
Flap endonuclease 1 (Fen1) is a structure-specific metallonuclease with important functions in DNA
replication and DNA repair. It interacts like many other proteins involved in DNA metabolic events with
proliferating cell nuclear antigen (PCNA), and its enzymatic activity is stimulated by PCNA in vitro.
The PCNA interaction site is located close to the C terminus of Fen1 and is flanked by a conserved basic
region of 35-38 amino acids in eukaryotic species but not in archaea. We have constructed two deletion
mutants of human Fen1 that lack either the PCNA interaction motif or a part of its adjacent C-terminal
region and analyzed them in a variety of assays. Remarkably, deletion of the basic C-terminal region did
not affect PCNA interaction but resulted in a protein with significantly reduced enzymatic activity.
Electrophoretic mobility shift analysis revealed that this mutant displayed a severe defect in substrate
binding. Our results suggest that the C terminus of eukaryotic Fen1 consists of two functionally distinct
regions that together might form an important regulatory domain.
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Flap endonuclease 1 (Fen1) is a structure-specific met-
allonuclease with important functions in DNA replica-
tion and DNA repair. It interacts like many other pro-
teins involved in DNA metabolic events with
proliferating cell nuclear antigen (PCNA), and its enzy-
matic activity is stimulated by PCNA in vitro. The PCNA
interaction site is located close to the C terminus of Fen1
and is flanked by a conserved basic region of 35–38
amino acids in eukaryotic species but not in archaea. We
have constructed two deletion mutants of human Fen1
that lack either the PCNA interaction motif or a part of
its adjacent C-terminal region and analyzed them in a
variety of assays. Remarkably, deletion of the basic C-
terminal region did not affect PCNA interaction but re-
sulted in a protein with significantly reduced enzymatic
activity. Electrophoretic mobility shift analysis re-
vealed that this mutant displayed a severe defect in
substrate binding. Our results suggest that the C termi-
nus of eukaryotic Fen1 consists of two functionally dis-
tinct regions that together might form an important
regulatory domain.
Fen1 (59 exonuclease-1 or flap endonuclease-1) is a multi-
functional structure-specific metallonuclease that is important
for DNA metabolic events such as replication and repair. Its
main function in replication is proposed to be the removal of the
displaced RNA-DNA primers synthesized by DNA polymerase
a-primase during discontinuous lagging strand replication (re-
viewed in Ref. 1). In DNA repair, Fen1 appears to be required
for nonhomologous end joining of double-strand DNA breaks
(2) and for the removal of DNA base damage and single-strand
breaks, likely through participation in the excision and resyn-
thesis steps of long patch base excision repair and nucleotide
excision repair (reviewed in Ref. 3). The relevance of these
observations is underscored by in vivo data using yeast Fen1-
null mutant strains that display severely impaired phenotypes
such as temperature sensitivity for growth with a terminal
phenotype consistent with a defect in replication, sensitivity for
DNA damaging agents such as UV radiation, and alkylating
agents and defects in telomere maintenance (4–7). Because
these deletion strains are strong mutators with destabilized
repetitive sequences, it has been suggested that Fen1 might
also be involved in one of the mechanisms by which trinucle-
otide expansions occur (8–10). Such expansions have been
identified as the bases of more than 10 human hereditary
diseases. In sum, Fen1 is a key enzyme for maintaining the
genomic stability.
The biochemistry of Fen1 has been studied extensively by
several groups (reviewed in Ref. 11), and the crystal structures
of two Fen1 orthologues from archaea have been solved (12, 13).
The enzyme seems to employ a unique cleavage mechanism for
substrates containing single stranded 59 tails or flap struc-
tures. It cleaves the flap by recognizing the 59 end, tracking the
length of the tail and cleaving at the junction between double-
stranded and single-stranded DNA (14). The crystal structures
of the archaea orthologues of Fen1 reveal a helical arch or
clamp above the globular domain that contains the active site.
This clamp forms a hole big enough for single-stranded but not
for double-stranded DNA. This structure might be utilized by
the nuclease to recognize and track down the 59 end of a flap
structure (13). DNA substrates containing nicks or small gaps
are also cleaved exonucleolytically by Fen1. Although Fen1 acts
less efficiently as an exonuclease than as a flap endonuclease,
it is likely that the enzyme employs similar mechanisms for
both reactions (11).
Eukaryotic Fen1 forms a stable complex with the replication
accessory protein PCNA1 both in vitro and in vivo, and under
physiological salt conditions PCNA can greatly stimulate the in
vitro activity of Fen1 (15–18). The interaction domain was
mapped to a region near the basic C terminus of Fen1, which
contains a consensus motif similar to that found in several
other replication and repair proteins that interact with PCNA
(15). Adjacent to the PCNA interaction motif at the very C
terminus, Fen1 from eukaryotic species carries a basic tail of
35–38 amino acids of unknown function. This basic tail is
absent in the solved x-ray structures of both archaea Fen1
orthologues. However, homologous basic tails are also present
at the C termini of the XP-G structure-specific nucleases
known to be involved in nucleotide excision repair (RAD2 of
Saccharomyces cerevisiae and Rad13 of Schizosaccharomyces
pombe). Here, this domain seems to be important for nuclear
localization and for dynamic response to UV radiation (19).
Consequently, it was suggested that in the case of Fen1, this
domain might as well contain a nuclear localization signal that
serves to translocate Fen1 into the nucleus where its activity is
required (20). In another report, it was proposed that the entire
C-terminal part of Fen1 might be important for PCNA inter-
action (17).
In the present study, we have constructed two deletion mu-
tants of human Fen1 lacking either the PCNA interaction motif
or a part of its adjacent C-terminal region and analyzed these
mutants in a variety of assays. Consistent with results of a very
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recent study (21), we found that the PCNA interaction motif is
indispensable for stimulation of Fen1 activity by PCNA. More-
over, our data reveal that the basic C-terminal tail is not
important for PCNA interaction. However, this part of the
protein is required for substrate binding. Our results indicate
two functionally distinct regions within the C-terminal part of
human Fen1 that might together form an important regulatory
domain.
EXPERIMENTAL PROCEDURES
Nucleic Acid Substrates—Oligonucleotides for preparing the sub-
strates for the Fen1 assays were purchased from Microsynth GmbH
(Balgach, Switzerland). Ft2_01 is a 39-mer composed of 19 nucleotides
complementary to nucleotides 698–717 of the plasmid pBluescript SK1
(pBS) and a 20-nucleotide noncomplementary tail. Ft2_05 is a 19-mer of
the same sequence without the noncomplementary tail, and Ft2_02 is a
30-mer complementary to nucleotides 669–698 of single-stranded pBS.
Oligonucleotides Ft2_01 and Ft2_05 were labeled at the 59 end using
[g-32P]ATP and T4 polynucleotide kinase. Free ATP was removed on
MicroSpinTM G-25 columns. To generate the substrates for the endo-
and exonuclease assays, the appropriate primers were mixed with sin-
gle-stranded pBS DNA in 1:1 molar ratio in 20 mM Tris-HCl, pH 7.4,
150 mM NaCl, heated to 75 °C, and slowly cooled to room temperature.
The templates for the mobility shift assay were created by hybridizing
59-labeled Ft2_01 or Ft2_05 and unlabeled Ft2_02 to a complementary
49mer oligonucleotide, corresponding to nucleotides 669–717 of pBS.
Enzymes and Proteins—Human Fen1 cDNA (gift of A. Dutta) was
cloned into the pET23d vector (Novoagene). Deletion mutagenesis was
performed with the QuickChangeTM site-directed mutagenesis kit from
Stratagene according to the instruction manual. The following primers
were used for the Fen1(DP) mutant (amino acids 337–344): 59-AA-
GAGCCGCCAAGGCAGCACCAAGGTGACCGGCTCACTCT-39 and 59-
AGAGTGAGCCGGTCACCTTGGTGCTGCCTTGGCGGCTCTT-39. For
the Fen1(DC) mutant (aa 360–380), oligos 59-GCGCAAGGAGCCAGA-
AGGAAAGCTTGCGGCCG-39 and 59-CGGCCGCAAGCTTTCCTTCTG-
GCTCCTTGCGC-39 were used, respectively. Wild type and mutant
Fen1 were overexpressed in Escherichia coli strain BL21(DE3)pLysS as
histidine-tagged proteins and purified to homogeneity via Nickel
charged metal chelating resin (HiTrap; Amersham Pharmacia Biotech)
and fast protein liquid chromatography MonoS chromatography. Hu-
man PCNA was produced in E. coli using the plasmid pT7/hPCNA (gift
from B. Stillman) and purified to homogeneity as described (22). Rep-
lication factor C (RF-C) was purified from nuclear extract of 60 g of
harvested HeLa cells as described (23). Human replication protein A
(RP-A) was overexpressed in E. coli strain BL21(DE3) harboring the
expression plasmid p11d-tRP-A and purified according to Ref. 24.
Native Gradient PAGE—The electrophoresis was performed in
8–25% polyacrylamide gels using the Phast System (Amersham Phar-
macia Biotech) according to the manufacturer’s instructions. The gels
were stained with Coomassie Blue.
Affinity Interaction Binding Assay—Interaction was measured as
described (25). Briefly, E. coli strain BL21(DE3)pLysS harboring either
wild type or mutant Fen1 and PCNA expression plasmids was grown at
37 °C, and expression was induced. After harvesting by centrifugation,
the cell pellets were resuspended in buffer A (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 10 mM pepstatin
A, 10 mg/ml leupeptin, 10 mg/ml aprotinin) and briefly sonicated. The
cell lysates were clarified by centrifugation. Binding assay mixtures
(500 ml) contained 50 ml of 50% nickel-nitrilotriacetic acid-Sepharose
resin (Invitrogen), 150 ml of each cell lysate, and 50 mM Tris-HCl, pH
7.5, 150 mM NaCl to increase mixing efficiency. These mixtures were
incubated for 90 min at 4 °C with constant gentle agitation and washed
six times with 0.8 ml of buffer B (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
60 mM imidazole), and bound protein complexes were subsequently
visualized on Coomassie-stained 12% SDS-polyacrylamide gels.
Fen1 Assay—The assays were performed in a final volume of 12.5 ml
containing 40 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol,
200 mg/ml bovine serum albumin, 50 fmol of DNA substrate, 50 ng of
RP-A, and indicated amounts of NaCl, ATP, PCNA, and RF-C. After
addition of wild type or mutant Fen1, the reactions were incubated at
30 °C for 15 min and stopped with 2.53 stop buffer (95% formamid, 20
mM EDTA, 0.05% each bromphenol blue, and Xylene cyanol). Products
were separated on 15% denaturing polyacryamid gels, visualized by
autoradiography and quantified on a PhosphorImager using the Image-
Quant software (Molecular Dynamics).
Mobility Shift Assay for Fen1—Binding reactions were carried out as
described (26). Briefly, a total volume of 20 ml contained 50 mM Tris-
HCl, pH 8, 10 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, 50 mg/ml bovine
serum albumin, 50 fmol of labeled oligonucleotide template, and indi-
cated amounts of wild type or mutant Fen1. After incubation at 20 °C
for 10 min, reactions were loaded on 7% polyacrylamide gels containing
0.53 TBE and run at 50 V for 3 h. The gels were dried and exposed to
x-ray films.
RESULTS
A Conserved Basic C-terminal Tail Flanks the PCNA-binding
Motif of Eukaryotic Fen1—The structures of archaea Fen1 re-
veal a saddle-shaped, single-domain a/b protein with a deep
positively charged cleft along one face and an unusual “helical
clamp” through which a single-stranded flap strand is likely
threaded. The C-terminal nine residues extend away from the
body of the enzyme (Fig. 1A and Refs. 12 and 13). These
residues are homologous to critical residues of eukaryotic pro-
teins known to interact with PCNA (15), and, based on these
data, a model of how Fen1 could be hooked to PCNA during
DNA replication was proposed (12). However, Fen1 from eu-
karyotic species have additional 35–38 residues at the C ter-
minus that are not present in the archaea enzymes (Fig. 1B).
Chen and colleagues (17) have deleted 17 residues at the very
C terminus of human Fen1 and tested this mutant for its
ability to interact with PCNA. Surprisingly, their mutant Fen1
FIG. 1. Mutations at the C terminus of human Fen1. A, structure
of Methnococcus jannaschii Fen1 (13). The region of homology to the
PCNA-binding motif in human Fen1 is indicated (P). The basic C-
terminal tail is not present in the archaea orthologue. B, sequence
alignment of the Fen1 C termini from various eukaryotic species. The
PCNA-binding motif and the basic C-terminal tail are shaded and the
conserved residues are printed in bold. C, SDS-PAGE analysis of puri-
fied wild type and mutant Fen1. 1.3 mg of each sample were separated
on a 12% SDS polyacrylamid gel and stained with Coomassie Blue.
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failed to interact with PCNA in several assays, although it still
contained an intact PCNA interaction motif. Thus, these C-
terminal residues could be involved in PCNA interaction, or
they could play another as yet unknown function. In a quest for
Fen1 mutants that would differ from wild type Fen1 in their
affinities for PCNA, we selectively deleted two regions at the C
terminus of human Fen1. The first deletion comprised the
entire PCNA interaction motif (amino acids 337–343) and was
called Fen1(DP). The second deletion mutation, called
Fen1(DC), enclosed the last 21 C-terminal amino acids (amino
acids 360–380). Wild type and mutant Fen1 were overex-
pressed in E. coli as polyhistidine (His6)-tagged proteins and
purified to homogeneity (Fig. 1C).
The Basic C Terminus of Human Fen1 Is Not Required for
PCNA Binding—First, we tested whether the C-terminal tail of
human Fen1 is involved in PCNA interaction. We have previ-
ously shown that the complex formed by PCNA and Fen1 is
stable enough to survive electrophoresis on native gels (15).
The complexes appear as shifted bands on Coomassie-stained
native gels (Fig. 2A). PCNA alone runs at about 67 kDa (lane
1), despite its actual mass of 86.3 kDa, reflecting the compact-
ness of the trimer and the high overall negative charge of the
protein. Fen1(WT) alone with an estimated pI of 8.78 does not
enter the gel because of its net positive charge at pH 8.44 of the
gel buffer, and the same is true for Fen1(DP) (lanes 2 and 3).
However, Fen1(DC) lacking several basic residues at the C
terminus slowly enters the gel and appears between 170–180
kDa (lane 4). By separating a mixture of equimolar amounts of
purified PCNA (as trimer) and Fen1(WT), a complex with a
molar mass of 263 kDa was apparent (lane 5). Most likely, the
high pI of Fen1 is responsible for the extent of the observed
band shift. A similar shift appeared when equimolar amounts
of PCNA and Fen1(DC) were separated, although in this case
the complex ran at around 190 kDa (lane 6). However, when
equimolar amounts of PCNA and Fen1(DP) were separated, no
such band shift could be observed (lane 7). This suggests that
Fen1(WT) and Fen1(DC) but not Fen1(DP) form complexes with
PCNA that are stable enough to survive native PAGE.
To confirm these findings, an affinity interaction assay was
used to compare the PCNA binding activities of wild type and
mutant Fen1. Lysates from bacteria expressing polyhistidine
(His6)-tagged wild type and mutant Fen1 and untagged PCNA
were mixed, and nickel-charged metal chelate resin was added
to capture the His6-tagged Fen1 along with any associated
PCNA (Fig. 2B). As expected, PCNA bound stably to Fen1(WT)
and Fen1(DC) (lane 5 and 6) but not at all to Fen1(DP) (lane 7).
The same results were obtained when His6-tagged PCNA was
used to pull down untagged wild type and mutant Fen1, thus
ruling out the possibility of a binding interference with the
polyhistidine tag (data not shown). Taken together, these data
suggested that the PCNA binding activity does not depend on
the presence of the basic C-terminal tail of human Fen1, al-
though a slight reduction in affinity cannot be ruled out.
A Fen1 Mutant Lacking 21 Amino Acids at the C Terminus Is
Defective for PCNA-independent Endo- and Exonuclease Activ-
ity—Fen1 cleaves endonucleolytically at branched DNA struc-
tures that have single-stranded 59 flaps and exonucleolytically
at nicks and, with lower efficiency, at gaps or recessed 59 ends
on double-stranded DNA. At low salt concentrations, Fen1
displays nuclease activity in the absence of its accessory pro-
tein PCNA. Wild type and mutant Fen1 nuclease activities
were first determined in a flap cleavage assay in the absence of
monovalent ions. The circular flap template was created as
described in the experimental section and is documented in
Fig. 3A. On this template, Fen1 cleaves at the junction of the
flap releasing a labeled 20-mer fragment, which was quanti-
tated by denaturing urea-polyacrylamide gel electrophoresis
(Fig. 3A). Under low salt conditions, the activity of Fen1(WT)
and Fen1(DP) was almost identical (Fig. 3A, lanes 2–4 and
5–7), whereas the activity of Fen1(DC) was clearly impaired
(lane 8–10). Although 2.5 ng (60 fmol) of Fen1(WT) and
Fen1(DP) cleaved 80 and 90% of the input template (50 fmol) in
15 min, respectively, the same amount of Fen1(DC) cleaved
only about 8% of the template. Thus, at nonsaturating enzyme
concentrations, Fen1(DC) is about 10 times less active than
Fen1(WT) and Fen1(DP). Fen1(DC) displayed a reduced enzy-
matic activity even at highly saturating enzyme concentrations
(25 ng; 0.6 pmol).
Next, we tested whether the exonucleolytic activity of the
mutant Fen1(DC) was impaired as well. Purified wild type and
mutant Fen1 were examined on a circular partial duplex DNA
molecule containing a nick (Fig. 3B). Fen1 digests the up-
stream oligonucleotide exonucleolytically in the 59 to 39 direc-
tion, thus releasing a labeled 59 mononucleotide, which could be
resolved and quantitated on 15% urea polyacrylamid gels. As
expected, Fen1(DC) exonucleolytic activity was also severely
FIG. 2. The mutant Fen1(DC) but not the mutant Fen1(DP) is able to interact with PCNA. A, samples containing 4 mg of PCNA (40 pmol
of trimer), 5 mg (120 pmol) of wild type, or mutant Fen1 and wild type or mutant Fen1 in combination with PCNA, respectively, were incubated
at 37 °C for 15 min, separated on a 8–25% native gradient gel using the Phast System (Amersham Pharmacia Biotech), and stained with Coomassie
Blue. Markers are ovalbumin (43 kDa), bovine serum albumin (67 kDa), aldolase (158 kDa), catalase (232 kDa), and ferritin (440 kDa). B,
nickel-nitrilotriacetic acid resin was incubated with cleared bacterial lysates from isopropyl-1-thio-b-D-galactopyranoside-induced cells containing
human PCNA expression plasmid (lane 1) and His6-tagged wild type and mutant human Fen1 expression plasmids (lanes 2–4). Cleared lysates
from cells expressing His6-tagged wild type (WT, lane 5) and mutant (DP, lane 6; DC, lane 7) Fen1 were mixed with nickel-nitrilotriacetic acid resin
and equal aliquots of lysates from bacteria expressing untagged PCNA. After washing, protein complexes were denatured, separated by
SDS-PAGE, and analyzed by Coomassie Blue staining. Arrows indicate the mobility of individual proteins.
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reduced (lanes 18–20). Again, the activities of Fen1(WT) and
Fen1(DP) were almost identical (Fig. 3B, lanes 12–14 and 15–
17). Although 5 ng of (120 fmol) of Fen1(WT) and Fen1(DP)
cleaved 84 and 81% of the input template (50 fmol) in 15 min,
respectively, no detectable cleavage product could be observed
when 50 fmol of the template was incubated with 5 ng of
Fen1(DC). When the same amount of template was incubated
together with 50 ng of Fen1(DC), only 24% were cleaved in 15
min. At these concentrations, Fen1(WT) and Fen1(DP) cleaved
almost 100%.
In summary, these data are in agreement with a recent study
by Gomes and Burgers (21) showing that a mutation within the
PCNA-binding motif does not affect the nuclease activity of
yeast Fen1 at low salt concentration. In addition, our data
reveal that the PCNA independent endo- and exonucleolytic
activities of a Fen1 mutant lacking the basic C-terminal tail are
severely defective when compared with wild type activity.
Both the PCNA-binding Motif and the C-terminal Tail of
Human Fen1 Are Important for PCNA-dependent Endo- and
Exonuclease Activity—Endo- and exonucleolytic activities of
Fen1 are inversely proportional to monovalent salt concentra-
tions in the physiological range (27). However, it has been
shown that PCNA can stimulate Fen1 activity up to 50-fold
under physiological salt conditions (16, 18). Kinetic analysis
revealed that PCNA enhances Fen1 binding stability, thus
increasing the cleavage efficiency (28). To efficiently stimulate
Fen1 activity, the PCNA trimer must encircle the DNA and
must be located “below” the flap (15). In our study, PCNA-de-
pendent Fen1 activity was determined at 100 mM NaCl. Under
these conditions, Fen1 alone is inactive (Fig. 4A). For stimula-
tion, the ATP-dependent clamp loader RF-C must be present to
load PCNA at the flap junction and at the position of the nick,
respectively, because PCNA cannot spontaneously load onto
circular DNA molecules in the absence of RF-C. The human
single-stranded DNA binding protein RP-A was also present in
this assay to prevent nonproductive association of RFC to sin-
gle-stranded DNA (29). First, wild type and mutant Fen1 nu-
clease activities were determined in the presence of 100 mM
NaCl (Fig. 4B). Fen1(DP) was inactive, even at the highest
concentration tested (lanes 5–7). This result is again in agree-
ment with a recently characterized similar yeast Fen1 mutant
(21), although this mutant carrying two point mutations within
the PCNA-binding motif shows weak activity at long incuba-
tion times. Fen1(DC) displayed some activity at higher concen-
trations, but this activity was also severely impaired compared
with Fen1(WT) activity; in the presence of PCNA, as little as
0.05 ng (1.2 fmol) Fen1(WT) cleaved 85% of the input template
in 15 min (lane 2), whereas the same amount of Fen1(DC)
cleaved only 8.5% (lane 8). Remarkably, the difference between
Fen1(WT) and Fen1(DC) activity seems to be the same as in the
FIG. 3. Fen1(DC) but not Fen1(DP)
activity is reduced in PCNA-inde-
pendent nuclease assays. Activity of
buffer alone (B) wild type (WT), and mu-
tant (DP and DC) Fen1 was measured in
the absence of ATP, PCNA and RF-C. Pro-
teins were titrated to 50 fmol of RP-A-
coated circular substrate in reaction
buffer containing no salt. Products were
separated on 15% urea polyacrylamid gels
and visualized by autoradiography.
Quantification was done with a Phosphor-
Imager. A, flap endonucleolytic activity.
The amounts of Fen1 were 0.25 ng (6
fmol), 2.5 ng (60 fmol), and 25 ng (0.6
pmol), respectively. B, exonucleolytic ac-
tivity. The amounts of Fen1 were 0.5 ng
(12 fmol), 5 ng (120 fmol), and 50 ng (1.2
pmol), respectively. Right panel, sche-
matic view of the circular flap and nicked
DNA substrates.
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absence of PCNA, although in the PCNA independent assay,
the enzyme concentration was 50-fold higher. When the PCNA-
dependent exonucleolytic activity of wild type and mutant Fen1
was tested, Fen1(DP) was, as expected, completely inactive
(lanes 15–17), and Fen1(DC) was about 10 times less active
than Fen1(WT) (lanes 12–14 and 18–20).
In summary, Fen1(DP) is completely defective under PCNA-
dependent conditions. Because this mutant is unable to form a
complex with PCNA (Fig. 2), we conclude that the physical
interaction between Fen1 and PCNA is absolutely required for
Fen1 stimulation. Moreover, PCNA-dependent endo- and exo-
nucleolytic activity of Fen1(DC) is as much reduced as the
PCNA-independent activity, which suggests that the C-termi-
nal tail has no influence on PCNA interaction and stimulation.
The C Terminus of Human Fen1 Is Essential for Substrate
Binding—Because Fen1(DC) activity was 10-fold reduced both
in PCNA-independent and in PCNA-dependent nuclease as-
says, we next tested whether this mutant had a defect in
substrate binding. To investigate the substrate binding char-
acteristics of wild type and mutant Fen1, we employed the
mobility shift assay developed by Harrington and Lieber (26).
Because Fen1 is a potent nuclease in the presence of divalent
metal ions, EDTA was included in the binding reaction. The
labeled binding substrates were created as described under
“Experimental Procedures.” Fen1(WT) and Fen1(DP) were
found to bind to both flap and nick substrates in a dose-depend-
ent manner. At concentrations between 60 and 240 nM of Fen1,
a single shifted species was observed (Fig. 5, lanes 2–7 and
12–17, respectively). However, when equal amounts of
Fen1(DC) were incubated with the binding substrates, no de-
tectable shift could be observed, indicating that this C-terminal
mutant displayed a severe defect in substrate binding, suggest-
ing that the reduced nuclease activity of this mutant is caused
by a defect in the binding portion of the nucleolytic reaction.
DISCUSSION
In this study, we have characterized two deletion mutants of
human Fen1 lacking residues at the C terminus that have been
proposed to be critical for interaction with PCNA. These mu-
tants were compared with wild type Fen1 in a variety of assays.
The mutant Fen1(DP) lacking 7 amino acids (amino acids 337–
343) near the C terminus behaved very similarly to mutants
recently characterized by other groups (21, 25). These studies
and the data presented here provide a consistent body of evi-
dence that the bimolecular interaction between these two pro-
teins is mediated by a consensus PCNA-binding motif (QXX(M/
I/L)XXF(F/Y)), which is present in several other proteins
known to interact with PCNA including p21, XP-G and DNA
ligase I. On the other hand, at least two regions within PCNA
seem to mediate the interaction with Fen1, and the protein-
protein contacts between Fen1 and PCNA are slightly different
in solution from the contacts that occur when the proteins are
complexed with DNA (15, 21). The relevance of the PCNA/Fen1
interaction via the interaction motif is underscored by in vivo
FIG. 4. Fen1(DP) is inactive and
Fen1(DC) activity is severely reduced
in PCNA-dependent Fen1 assays. Ac-
tivity of buffer alone (B), wild type (WT),
and mutant (DP and DC) Fen1 was meas-
ured in the presence of 1 mM ATP, 0.5
pmol of PCNA, and 2.5 pmol of RF-C.
Proteins were titrated to 50 fmol of RP-A-
coated circular substrate in reaction
buffer containing 100 mM NaCl. Products
were separated on 15% urea polyacryl-
amid gels and visualized by autoradiogra-
phy. Quantification was done with a
PhosphorImager. A, flap endonucleolytic
activity. The amounts of Fen1 were 0.05
ng (1.2 fmol), 0.5 ng (12 fmol), and 5 ng
(120 fmol), respectively. B, exonucleolytic
activity. The amounts of Fen1 were 0.1 ng
(2.4 fmol), 1 ng (24 fmol), and 10 ng (240
fmol), respectively. C, depletion of the as-
say reveals that Fen1 activity is depend-
ent on the presence of both PCNA and
RF-C.
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data using yeast strains with mutations within this conserved
region (21, 30). In another report, it was suggested that the
basic C-terminal tail of Fen1 was also important for the inter-
action with PCNA, because a deletion mutant lacking 17 amino
acids at the C terminus failed to interact with PCNA, although
this mutant still contained an intact PCNA interaction motif
(17). We have constructed a similar mutant, Fen1(DC), lacking
21 amino acids at the very C terminus and tested it for PCNA
interaction in a native PAGE-based assay and in an affinity
interaction binding assay. In our hands, no difference in the
ability to interact with PCNA could be detected between this
mutant and wild type Fen1, whereas the Fen1(DP) mutant was
completely unable to interact with PCNA. This discrepancy
may partially result from differences in the experimental de-
sign or alternatively the additional C-terminal residues on the
Fen1 mutant of Chen et al. (17) may affect the folding of the
PCNA-binding motif so that it no longer can interact with
PCNA. Our data, however, show that the short PCNA-binding
motif of Fen1 is responsible for the bulk of the PCNA interac-
tion. Consistent with this, we showed in this study that wild
type Fen1 and the Fen1(DC) mutant were stimulated by PCNA
to a relatively equal extent under physiological salt conditions.
On the other hand, both the endo- and exonucleolytic activ-
ities of the mutant Fen1(DC) were significantly reduced com-
pared with the wild type enzyme. This defect could be observed
in a PCNA-dependent background, as well as under conditions
where Fen1 displays activity without PCNA. We therefore con-
clude that this defect is not due to the inability of Fen1(DC) to
interact with PCNA. Moreover, the ability of this mutant to
associate with an oligo flap template and a short nicked double-
stranded DNA was severely reduced. Our results clearly dem-
onstrate the importance of the C-terminal basic tail for the
binding portion of the nucleolytic reaction. Because the active
site of the enzyme is composed of residues of the N-terminal
and intermediate conserved regions (31, 32), it is rather un-
likely that the C terminus is also involved in the cleavage
portion of the enzymatic reaction. The simplest explanation for
the defect in substrate binding of Fen1(DC) would be the lack of
several positively charged residues (8 lysines and 1 arginine)
that may specifically or unspecifically contact the negatively
charged phosphate groups of the DNA backbone and contribute
to the stability of the enzyme substrate complex. If this is true,
then the question arises why such an “anchor” is not present in
the archaea Fen1 orthologues, which have structure-specific
mechanisms for DNA substrate binding and catalysis resem-
bling the human enzyme (33). Another even more interesting
possibility would be that the C-terminal tail loops back toward
the enzymatic center, thus providing structural elements that
might modulate the stability of the enzyme substrate complex.
We could recently show that Fen1 is an acetylated protein in
vivo.2 This Fen1 acetylation is significantly increased after UV
treatment of the cells and is most probably mediated by the
histoneacetyl transferase domain of the transcriptional coacti-
vator p300. There is a detectable interaction between these two
proteins both in vitro and in vivo, which is mediated by the
C-terminal tail of Fen1. Moreover, we showed that the acety-
lated Fen1 possessed a reduced enzymatic activity, thus resem-
bling our Fen1(DC) mutant. Possibly, one or several lysine
residues at the C-terminal tail are “neutralized” upon acetyla-
tion, which could lead to a destabilized enzyme-substrate com-
plex, as shown here for the Fen1(DC) mutant. This model
suggests that the C-terminal tail of eukaryotic Fen1 contains
regulatory regions that are modified upon treatment of the
cells with damaging agents. This modification might regulate
the enzymatic activity itself or the subnuclear localization by
modulating the DNA binding stability and/or specificity. In
summary, our results suggest that the C terminus of eukary-
otic Fen1 consists of two functionally distinct regions: one that
mediates PCNA interaction, which is important for stimulation
of enzymatic activity and/or targeting Fen1 to sites where its
action is required, and a second region that functions in recog-
nition of the DNA substrate. This second region is not present
in archaea orthologues of Fen1. It therefore has been suggested
that it might be required for nuclear localization of the enzyme
in eukaryotes (20, 34), although the importance of such a pu-
tative nuclear targeting signal for Fen1 has not been shown.
Our data suggest that this basic C-terminal tail of eukaryotic
Fen1 most likely has an additional function.
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